Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 12, 2025 16:05 ET | Source: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Initial clinical data for BDC-4182 Phase 1 dose escalation study expected in 3Q 2026 Cash balance of $38.8 million as of September 30, 2025 anticipated to fund key milestones into 2027 REDWOOD CITY,...
October 01, 2025 16:05 ET | Source: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027

Initial clinical data for BDC-4182 Phase 1 dose escalation study now expected in 3Q 2026Company is implementing a 50% workforce reduction to extend cash runway into 2027 REDWOOD CITY, Calif., Oct. ...
August 14, 2025 16:05 ET | Source: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Next-generation claudin 18.2 ISAC BDC-4182 now in Phase 1 dose-escalation study Cash balance of $48.5 million as of June 30, 2025 anticipated to fund key milestones through mid-2026 REDWOOD CITY,...
May 12, 2025 16:05 ET | Source: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

BDC-4182 Phase 1 dose-escalation study now open for enrollmentBDC-3042 Phase 1 dose-escalation data presented at AACR 2025 demonstrated a favorable safety profile, dose-dependent biological activity,...
May 08, 2025 08:00 ET | Source: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 Results and Corporate Updates

Conference call and webcast on Monday, May 12, 2025, at 2:30 p.m. PT / 5:30 p.m. ET REDWOOD CITY, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a biopharmaceutical...
April 30, 2025 16:05 ET | Source: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics Presents Preclinical Results for Next-Generation Boltbody™ ISACs targeting CEA and PD-L1 at AACR Annual Meeting 2025

CEA-targeted ISAC elicits complete responses in mice and is well-tolerated in NHPs PD-L1 ISAC directly activates and reprograms PD-L1-expressing myeloid cells in the TME to drive complete responses...
April 25, 2025 13:00 ET | Source: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025

BDC-3042 was well tolerated up to 10 mg/kg q2w with no dose-limiting toxicities and no drug-related serious adverse events BDC-3042 showed biological activity, with clear dose-dependent increases in...
March 25, 2025 16:30 ET | Source: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics to Present Data from Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025

REDWOOD CITY, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer,...
March 24, 2025 16:20 ET | Source: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

BDC-4182 on track to start a clinical trial in gastric cancer in second quarter 2025BDC-3042 Phase 1 clinical trial fully enrolled the highest dose cohort with no dose-limiting toxicities (DLTs),...
February 25, 2025 16:05 ET | Source: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics to Participate in Upcoming March Conferences

REDWOOD CITY, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer,...